Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29362376 | 1.00 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL6860387 | 0.92 | CNR1 (0.84) | CNR1CNR2 | |
| SCHEMBL9640540 | 0.91 | CNR1 (0.83) | CNR1CNR2 | |
| SCHEMBL9037660 | 0.89 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL17025802 | 0.87 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL17025839 | 0.86 | CNR1 (0.80) | CNR1CNR2 | |
| SCHEMBL10666293 | 0.84 | CNR1 (0.73) | CNR1CNR2 | |
| SCHEMBL29388191 | 0.84 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL16922129 | 0.84 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL21179005 | 0.83 | CNR1 (0.71) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660283-B2 | Cannabinoid-containing composition | JOYN BOTANICALS LTD. (CA) | 2023-05-30 | — | — | US | claimed |
| EP-3897732-A1 | CANNABINOID-CONTAINING COMPOSITION | Joyn Botanicals Ltd. (CA) | 2021-10-27 | — | — | EP | claimed |
| US-20210308095-A1 | Cannabinoid-Containing Composition | JOYN BOTANICALS LTD. (CA) | 2021-10-07 | — | — | US | claimed |
| US-20200197353-A1 | Cannabinoid-Containing Composition | JOYN BOTANICALS LTD. (CA) | 2020-06-25 | — | — | US | claimed |
| WO-2020128767-A1 | CANNABINOID-CONTAINING COMPOSITION | ARTISS JOSEPH D (CA) | 2020-06-25 | — | — | WO | claimed |
| US-11660283-B2 | Cannabinoid-containing composition | JOYN BOTANICALS LTD. (CA) | 2023-05-30 | — | — | US | disclosed |
| US-20220026380-A1 | NUCLEAR MAGNETIC RESONANCE IMPLEMENTED SYNTHETIC INDOLE AND INDAZOLE CANNABINOID DETECTION, IDENTIFICATION, AND QUANTIFICATION | HOFSTRA UNIVERSITY (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3897732-A1 | CANNABINOID-CONTAINING COMPOSITION | Joyn Botanicals Ltd. (CA) | 2021-10-27 | — | — | EP | disclosed |
| US-20210308095-A1 | Cannabinoid-Containing Composition | JOYN BOTANICALS LTD. (CA) | 2021-10-07 | — | — | US | disclosed |
| EP-2989452-B1 | NUCLEAR MAGNETIC RESONANCE BASED SYNTHETIC INDOLE AND INDAZOLE CANNABINOID DETECTION, IDENTIFICATION, AND QUANTIFICATION | HOFSTRA UNIV (US) | 2021-09-29 | — | — | EP | disclosed |
| US-11085891-B2 | Nuclear magnetic resonance implemented synthetic indole and indazole cannabinoid detection, identification, and quantification | HOFSTRA UNIVERSITY (US) | 2021-08-10 | — | — | US | disclosed |
| WO-2020232350-A1 | ASSAYS FOR SYNTHETIC CANNABINOIDS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2014176542-A1 | NUCLEAR MAGNETIC RESONANCE IMPLEMANTED SYNTHETIC INDOLE AND INDAZOLE CANNABINOID DENTECTION, IDENTIFICATION, AND QUANTIFICATION | HOFSTRA UNIVERSITY (US) | 2014-10-30 | — | — | WO | disclosed |
| EP-2698385-A1 | Detection of synthetic cannabinoids | Randox Laboratories Ltd. (GB) | 2014-02-19 | — | — | EP | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | Unversity of Washington Through its Center for Commercialization (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2013106460-A2 | COMPOSITIONS AND METHODS FOR TREATING MALIGNANT ASTROCYTOMAS | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2013-07-18 | — | — | WO | disclosed |
| US-20120208213-A1 | Detection of Synthetic Cannabinoids | RANDOX LABORATORIES LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| EP-2487155-A1 | Detection of Synthetic Cannabinoids | Randox Laboratories Ltd. (GB) | 2012-08-15 | — | — | EP | disclosed |
| WO-2012024670-A2 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197026-A1 | COMPOSITION AND METHODS FOR TREATING GLIOBLASTOMA | MGMT, NEFM, TP53 | CNR1 2351/4885CNR2 1823/4885 |
| US-20120208213-A1 | Detection of Synthetic Cannabinoids | CNR2, CNR1, FAAH | CNR1 2/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.